People · Operator
Named in public records as an officer, director or promoter · active 2021–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vita Therapeutics, Inc. | — | Biotechnology | Series B | $62.9M | $461.0M | 2021 |
| Osmol Therapeutics, Inc. | — | Biotechnology | Seed | $2.9M | $41.5M | 2022 |
Vlad Coric at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Vlad Coric on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Berman | 1 | 4 |
| Pat LaVecchia | 1 | 3 |
| James Peyer | 1 | 3 |
| DAVID CHURCHILL | 1 | 3 |
| Brian Dixon | 1 | 3 |
| Robert Linke | 1 | 2 |
| Douglas Falk | 1 | 1 |
| Eva Chin | 1 | 1 |
| Mark Nuttall | 1 | 1 |
| Faizzan Ahmad | 1 | 1 |
| Michael Ehrlich | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.